Anxiety DisordersDepressive DisordersHealthy VolunteersMicrodosingCreativityLSD

Greater subjective effects of a low dose of LSD in participants with depressed mood

This double-blind, randomised, placebo-controlled, crossover trial (n=39) finds a low dose of LSD (26μg) to produce greater positive mood, stimulant-like, and psychedelic effects in people with mild depression (BDI-II≥17) compared to non-depressed controls. Self-rated depression scores decreased more 48 hours after LSD for the mildly depressed group. Both groups showed expected physiological and subjective drug effects. This suggests low-dose LSD may have therapeutic potential for depression.

Authors

  • Harriet de Wit
  • Richard Lee

Published

Neuropsychopharmacology
individual Study

Abstract

Recent studies and anecdotal reports suggest that psychedelics can improve mood states, even at low doses. However, few placebo-controlled studies have examined the acute effects of low doses of LSD in individuals with psychiatric symptoms. In the current study, we examined the acute and sub-acute effect of a low dose of LSD (26 µg) on subjective effects and mood in volunteers with mild depressed mood. The study used a randomized, double-blind, crossover design to compare the effects of LSD in two groups of adults: participants who scored high (≥17; n = 20) or low (<17; n = 19) on the Beck Depression-II inventory (BDI) at screening. Participants received a single low dose of LSD (26 µg) and placebo during two 5-h laboratory sessions, separated by at least one week. Subjective, physiological, and mood measures were assessed at regular intervals throughout the sessions, and behavioral measures of creativity and emotion recognition were obtained at expected peak effect. BDI depression scores and mood ratings were assessed 48-h after each session. Relative to placebo, LSD (26 µg) produced expected, mild physiological and subjective effects on several measures in both groups. However, the high BDI group reported significantly greater drug effects on several indices of acute effects, including ratings of vigor, elation, and affectively positive scales of a measure of psychedelic effects (5D-ASC). The high BDI group also reported a greater decline in BDI depression scores 48-h after LSD, compared to placebo. These findings suggest that an acute low dose of LSD (26 µg) elicits more pronounced positive mood and stimulant-like effects, as well as stronger altered states of consciousness in individuals with depressive symptoms, compared to non-depressed individuals.

Available with Blossom Pro

Research Summary of 'Greater subjective effects of a low dose of LSD in participants with depressed mood'

Introduction

Depression remains a common, disabling condition for which many patients do not respond to standard treatments. Recent clinical and preclinical work has focused on high, single-dose psychedelic treatments (for example psilocybin or LSD combined with psychotherapy), but these approaches are resource intensive and carry risks. Anecdotal reports and surveys have suggested that very low ‘‘microdoses’’ of psychedelics can improve mood, mental health and creativity without overt perceptual disruption, yet controlled studies in healthy volunteers have mostly failed to confirm robust benefits. One important gap is that prior placebo-controlled microdose trials have largely tested healthy adults; it remains possible that low doses produce detectable effects only in individuals who have baseline negative mood or depressive symptoms. Molla and colleagues set out to test whether a single low dose of LSD (26 µg) produces stronger acute and short-term mood effects in volunteers with elevated depressive symptoms compared with non-depressed volunteers. The study used a randomized, double-blind, placebo-controlled, crossover design to compare subjective, physiological, behavioural and 48-hour follow-up mood measures in two groups defined by Beck Depression Inventory-II (BDI) scores at screening (high BDI ≥17, low BDI <17). The investigators aimed to capture both in-session effects and sub-acute changes 48 hours after dosing.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Study Details

References (21)

Papers cited by this study that are also in Blossom

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)

656 cited
Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial

Sloshower, J. A., Skosnik, P. D., Safi-Aghdam, H. et al. · Journal of Psychopharmacology (2023)

Microdosing psychedelics: Motivations, subjective effects and harm reduction

Lea, T., Amada, N., Jungaberle, H. et al. · International Journal of Drug Policy (2020)

95 cited
Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers

Hutten, N. P. W., Mason, N. L., Dolder, P. C. et al. · Frontiers in Psychiatry (2019)

Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study

de Wit, H., Molla, H. M., Bershad, A. K. et al. · Addiction Biology (2022)

Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers

Bershad, A. K., Schepers, S. T., Bremmer, M. P. et al. · Biological Psychiatry (2019)

Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study

Cavanna, F., Muller, S., de la Fuente, L. A. et al. · Translational Psychiatry (2022)

90 cited
Show all 21 references
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study

Marschall, J., Fejer, G., Lempe, P. et al. · Journal of Psychopharmacology (2021)

Self-blinding citizen science to explore psychedelic microdosing

Szigeti, B., Kartner, L., Blemings, A. et al. · eLife (2021)

128 cited
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing

Kaertner, L. S., Steinborn, M. B., Kettner, H. et al. · Scientific Reports (2021)

112 cited
Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants

Zhang, D. Z., Holze, F., Liechti, M. E. et al. · Clinical Pharmacology and Therapeutics (2020)

49 cited
The pharmacology of lysergic acid diethylamide: a review

Passie, T., Halpern, J. H., Stichtenoth, D. O. et al. · CNS Neuroscience and Therapeutics (2008)

Psychometric evaluation of the altered states of consciousness rating scale (OAV)

Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)

Acute effects of lysergic acid diethylamide in healthy subjects

Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)

Psychedelics promote structural and functional neural plasticity

Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)

Psychedelics promote plasticity by directly binding to BDNF receptor TrkB

Moliner, R., Girych, M., Brunello, C. A. et al. · Nature Neuroscience (2023)

Psychedelic Cognition-The Unreached Frontier of Psychedelic Science

Balaet, M. · Frontiers in Neuroscience (2022)

Cited By (10)

Papers in Blossom that reference this study

LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial

Daldegan-Bueno, D., Donegan, C. J., Sumner, R. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2026)

LSD microdosing in major depressive disorder: results from an open-label trial

Daldegan-Bueno, D., Donegan, C. J., Sumner, R. L. et al. · Neuropharmacology (2026)

What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial

Joy Donegan, C., Daldegan-Bueno, D., Sumner, R. L. et al. · Therapeutic Advances in Psychopharmacology (2025)

Participant Experiences of Microdosed Lysergic Acid Diethylamide in a 6-Week Randomised Controlled Trial

Murphy, R. J., Wardlaw, M., Smith, T. et al. · Journal of Humanistic Psychology (2025)

Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults A Randomized Clinical Trial

Mueller, L., de Jesus, N. M. S., Schmid, Y. et al. · JAMA Psychiatry (2025)

Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover Study

Arikci, D., Holze, F., Mueller, L. et al. · Clinical Pharmacology and Therapeutics (2025)

1 cited
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research

Polito, V., Liknaitzky, P. · Journal of Psychopharmacology (2024)

Microdosing psychedelics: Current evidence from controlled studies

Murphy, R., Muthukumaraswamy, S., De Wit, H. · Biological Psychiatry (2024)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

Greater subjective effects of a low dose of LSD... — Research Summary & Context | Blossom